Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 533.24 M
The data is delayed by 15 minutes.
Description: Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has three clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; rucaparib, an oral inhibitor of poly polymerase that is being explored in Phase II or III clinical trials for treating ovarian cancer patients, and Phase II clinical trials for treating pancreatic cancer patients; and lucitanib, an oral inhibitor of the tyrosine kinase Phase I/IIa clinical trials for the treatment of breast and lung cancers. The company's drug discovery program includes the discovery of cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. It has license agreements w
|Shares Outstanding||38.39 M||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||2.11||Price/Cash Per Share|
|Price/Free Cash Flow||-4.47||ROA||-27.31%||ROE||-76.19%||ROI|
|Current Ratio||7.93||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.22|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||1.19 M||Cash From Investing Activities||-143.03 M||Cash From Operating Activities||-48.41 M||Gross Profit|
|Net Profit||-63.14 M||Operating Profit||-64.22 M||Total Assets||704.71 M||Total Current Assets||441.7 M|
|Total Current Liabilities||55.68 M||Total Debt||287.5 M||Total Liabilities||452.12 M||Total Revenue|
|High 52 week||32.67||Low 52 week||3.12||Last close||3.21||Last change||2.88%|
|RSI||20.96||Average true range||0.29||Beta||1.33||Volume||1.42 M|
|Simple moving average 20 days||-17.78%||Simple moving average 50 days||-36.87%||Simple moving average 200 days||-80.19%|
|Performance Week||1.58%||Performance Month||-43.19%||Performance Quart||-73.97%||Performance Half||-84.87%|
|Performance Year||-87.99%||Performance Year-to-date||-82.13%||Volatility daily||3.69%||Volatility weekly||8.26%|
|Volatility monthly||16.93%||Volatility yearly||58.65%||Relative Volume||1318.58%||Average Volume||3.84 M|
|New High||New Low|
2021-03-25 11:30:03 | Why Is Clovis CLVS Up 4.4% Since Last Earnings Report?
2021-03-22 09:50:38 | Return On Capital Employed Overview: Clovis Oncology
2021-03-22 08:34:12 | Are Options Traders Betting on a Big Move in Clovis Oncology CLVS Stock?
2021-03-22 07:17:11 | Clovis CLVS Stock Jumps 47.7%: Will It Continue to Soar?
2021-03-19 16:30:00 | Why Clovis Oncology Stock Skyrocketed Today
2021-03-19 11:13:50 | Return On Capital Employed Overview: Clovis Oncology
2021-03-19 09:24:00 | 5 Top Stock Gainers for Friday: FedEx, Dollar General, Clovis
2021-03-19 08:19:00 | Clovis Oncology stock soars after ovarian cancer treatment meets primary endpoint
2021-03-19 08:00:00 | Clovis Oncology’s Rubraca® rucaparib Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation
2021-03-19 06:50:00 | Clovis Oncology Skyrockets on Ovarian Cancer Drug Success
2021-03-02 10:21:24 | Understanding Clovis Oncology's Unusual Options Activity
2021-02-23 09:24:35 | Clovis Oncology: Q4 Earnings Insights
2021-02-23 08:00:00 | Clovis Oncology Announces 2020 Operating Results
2021-02-23 06:30:00 | Clovis Oncology, Inc. to Host Earnings Call
2021-02-22 10:14:21 | Earnings Preview for Clovis Oncology
2021-02-02 10:00:03 | Alexion ALXN to Report Q4 Earnings: What's in the Cards?
2020-12-30 06:49:11 | Clovis CLVS Seeks Permission for Clinical Study on Novel Drug
2020-12-22 10:28:03 | Company News for Dec 22, 2020
2020-12-22 10:05:03 | Clovis' CLVS Rubraca Confirmatory Study Meets Endpoint
2020-12-21 10:05:16 | Looking Into Clovis Oncology's Return On Capital Employed
2020-12-21 08:00:00 | Clovis Oncology’s Rubraca® rucaparib Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation
2020-12-16 22:51:55 | Is CLVS A Good Stock To Buy Now?
2020-12-10 08:55:01 | Is the Options Market Predicting a Spike in Clovis Oncology CLVS Stock?
2020-12-05 11:32:04 | Clovis CLVS Up 18.6% Since Last Earnings Report: Can It Continue?
2020-11-24 18:06:00 | Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024
2020-11-20 08:00:00 | Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
2020-11-06 10:43:03 | Clovis CLVS Q3 Earnings Top, Sales Show Coronavirus Impact
2020-11-05 09:25:02 | Clovis Oncology CLVS Reports Q3 Loss, Lags Revenue Estimates
2020-11-05 08:05:00 | Clovis Oncology Announces Third Quarter 2020 Operating Results
2020-10-29 12:35:04 | Will Clovis Oncology CLVS Report Negative Earnings Next Week? What You Should Know
2020-10-14 22:15:23 | Hedge Funds Are Dipping Their Toes Back Into Clovis Oncology Inc CLVS
2020-10-13 06:47:33 | How Much Is Clovis Oncology, Inc. NASDAQ:CLVS Paying Its CEO?
2020-09-08 08:53:12 | Are Options Traders Betting on a Big Move in Clovis Oncology CLVS Stock?
2020-09-05 11:31:03 | Clovis CLVS Down 17.3% Since Last Earnings Report: Can It Rebound?
2020-08-27 09:58:02 | ROCE Insights For Clovis Oncology